Document is current
Any future updates will be listed below
-
Authors
Kong, Tim https://orcid.org/0000-0002-3240-8989
Laranjeira, Angelo B. A.
Letson, Christopher T.
Yu, LaYow
He, Fan
Jayanthan, Aarthi
Los, Gerrit
Dunn, Sandra E.
Challen, Grant A. https://orcid.org/0000-0003-4669-8814
Oh, Stephen T. https://orcid.org/0000-0002-8564-5400
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01HL134952, R01HL147978)
- License Information
-
More Information
Article History
Received: 3 October 2024
Revised: 31 October 2024
Accepted: 5 November 2024
First Online: 26 November 2024
Competing interests
: STO has served as a consultant for Kartos Therapeutics, CTI BioPharma, Celgene/Bristol Myers Squibb, Disc Medicine, Protagonist, Blueprint Medicines, Cogent, PharmaEssentia, Constellation, Geron, Abbvie, Sierra Oncology, and Incyte. MH, GL, and SED, are employees of Phoenix Molecular Designs. GAC has received funding for consulting and/or sponsored research from Incyte, Ajax Therapeutics, and Renagade Therapeutics. All other authors disclose no competing interests.
